Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Microsoft Threat Intelligence observed limited activity by an unattributed threat actor using a publicly available, static ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Our zLabs research team has discovered a mobile malware campaign consisting of almost 900 malware samples primarily targeting ...